A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients

Chinese Journal of Lung Cancer

Volumn 9, Issue 3, 2006, Pages 254-258

  Sun, Yan ^a   Zhu, Hongsheng ^b   Zhu, Yunzhong ^b   Feng, Jifeng ^b   Chen, Zhengtang ^b   Li, Gongshu ^b   Zhang, Xiangru ^b   Zhang, Zongqi ^b   Tang, Junfang ^b   Shi, Meiqi ^b   Hao, Xuezhi ^b   Han, Hui ^b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b NONE

Author keywords

Advanced non small cell lung cancer; Double blind trial; Mean survivaltime; Median survival time; NP regimen Rg3 of Gensing; Response rate

Indexed keywords

CISPLATIN; GENSING RG3; GINSENG EXTRACT; NAVELBINE; PLACEBO; UNCLASSIFIED DRUG;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CACAO; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPATHOLOGY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TABLET; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 33745736315     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Sun Y, Yu GQ ed. Integration of traditional chinese medicine & western medicine in the prevention and treatment of cancer. Beijing: Union Publishers of PUMC & Beijing University of Medicine, 1995, 76-82, 86-91.
2. Shinkai K, Akedo H, Mukai M, et al. Inhibition of in vitro tumor cell invasion by ginsenoside Rg3. Jpn J Cancer Res, 1996, 87(4): 357-362.
3. Gao Y, Wang JJ, Xu Q, et al. Inhibitory effect of ginsenoside Rg3 on tumor neoangiogenesis. Acad J Sec Mil Med Univ, 2001, 22 (1): 40-42.
4. Yi C, Huang XB, Hou M. Laboratory study of Rg3 in combination of chemotherapy in the treatment of lung cancer. Chin J Integrated Traditional Western Med, 2005, 25(1): 58-59.
5. Liu JW, Chen JX, Yu LH. et al. Inhibitory effect of ginsenoside-Rg3 on lung metastasis of mouse melanoma transfected with ribonuclease inhibitor. Chin J Oncol, 2004, 26(12): 722-725.
6. Zhang PT, Pu BK. et al. Clinical phase II study of Rg3 capsules. Chin J New Drugs, 1999, 8: 328-330.
7. Li ST, Sun Y. Past, present status, and future of tumor angiogenesis inhibitors in the management of common malignancies. Oncol Prog, 2003, 1: 80-87.
8. Wang JW, Sun Y, Liu YY. et al. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer, 2005, 8(4): 283-290.
9. Zhang XR, Sun Y, Kong WH, et al. Navelbine plus cisplatin combination therapy in the treatment of non-small cell lung cancer: a report of 42 cases. Chin J Oncol, 1998, 20(1): 60-62.
10. Sun Y, Zhao P ed. Recent advances of clinical oncology. Beijing: Peking Union Medical College Press, 2005, 256-274, 496-507.
11. Zhang ZX, Zhou QH. Advances of the traditional Chinese medicine in antiangiogenic therapy of tumors. Chin J Lung Cancer. 2006, 9 (1): 96-99.